AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02689869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA 101
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
Study NCT02357706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP A (ResMed AirSense AutoSet)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
Study NCT02357706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APAP B (Apex iCH Auto)
Description: Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
Study NCT02234596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
Study NCT04894552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma
Description: Patients with endometrial carcinoma will undergo laparoscopic hysterectomy and sentinel lymph node biopsy. The patient will be positioned in a modified lithotomy position with the hips flexed 30 degrees. Blue dye is injected at the cervix. The round ligament will be transected. Sentinel lymph nodes will be detected, dissected and isolated. Then standard lymphadenectomy will be done. Then the infundibulopelvic ligament will be transected. Ligation of the uterine vessels. The cardinal ligaments will be transected, and the vaginal fornices will be opened laparoscopically. The whole specimen will be removed through the vagina. The vaginal cuff will be then closed trans-vaginally. Intraoperative and early postoperative complications will be assessed. The isolated sentinel lymph node will be sent for pathological study as well as the standard lymphadenectomy specimens. Both specimens will be compared to assess the diagnostic reliability and sensitivity of the sentinel lymph node.
Study NCT01904214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: Treatment with a single oral dose of 0.25 mg BAF312
Study NCT03631914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular brachial plexus block
Description: An infraclavicular brachial plexus block is performed using ultrasound guidance.
Study NCT03631914 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Infraclavicular brachial plexus block
Description: An infraclavicular brachial plexus block is performed using ultrasound guidance.
Study NCT01873456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial nutritional intervention
Study NCT02589327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
Study NCT01955772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral nutrition alanyl-glutamin, Dipeptiven
Description: Enteral nutrition versus parenteral nutrition
Study NCT01955772 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enteral nutrition alanyl-glutamin, Dipeptiven
Description: Enteral nutrition versus parenteral nutrition
Study NCT02253316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixazomib
Study NCT02253316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02253316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00697086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Study NCT00697086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02644629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
Study NCT02644629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine (1st phase)
Description: Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
Study NCT02644629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine (2st phase)
Description: Patients failing to achieve response (\<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
Study NCT02262689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
Study NCT02262689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo will be supplied as gelatin capsule to be administered orally
Study NCT02051140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Strawberry
Description: 12g freeze-dried strawberry (powder), twice daily with water, for 90 days
Study NCT02051140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry Placebo
Description: 12g blue, strawberry-flavored powder, twice daily with water, for 90 days
Study NCT03339193 — intervention group
Intervention type: DEVICE
Intervention: Left atrial appendage closure
Description: Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
Study NCT01193465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Datex Ohmeda excel anesthesia machine
Description: maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
Study NCT01193465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Datex Ohmeda Avance anesthesia work-station
Description: maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
Study NCT01193465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drager Cato anesthesia work-station
Description: maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
Study NCT01193465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drager Primus anesthesia work-station
Description: maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
Study NCT01491204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+HM30181
Description: oral, 3times for 4weeks
Study NCT01346189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Economic Intervention
Description: Various combinations of financial incentives to patients and providers.
Study NCT01173731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT00654992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin-Beta
Description: 300 IU/kg of EPO or saline intravenously before surgery
Study NCT00654992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 300 IU/kg of normal saline intravenously before surgery
Study NCT02458339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir
Description: Surgical catheter placement into the fourth ventricle of the brain
Study NCT02969005 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
Study NCT02458339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
Study NCT00330343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone
Description: continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
Study NCT02951533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
Study NCT02951533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric Acid Esters
Description: Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
Study NCT01961895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus (LP) block analgesia
Study NCT01961895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient-controlled analgesia
Study NCT02600845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCU-CHEK
Description: ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
Study NCT04588051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60mg daily
Study NCT04590508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: The xanthohumol supplement will be administered in a capsule and taken orally.
Study NCT04590508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in a capsule and taken orally.
Study NCT04622514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Village doctor-led telemedicine integrated care
Description: 1. Reorienting the model of care: using of telemedicine platform and online consulting clinic; 2. Coordinating services: contract service by village doctor and on-line AF specialist; 3. Empowering and engaging people: provide village doctor ABC pathway training course; regular visit and drug delivery by village doctor (community support); patients and their family members education.
Study NCT04622514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 1. Usual care; 2. Intensified education to patients, their family members, and their village doctors.
Study NCT00642096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Study NCT00642096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Study NCT00642096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study NCT00642096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Study NCT03902522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: 2 injections of PRO 140 (2 X 2 mL/inj.)
Study NCT02989272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfate, Magnesium
Description: magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
Study NCT02989272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline group
Description: saline group (30 patients) who will receive pretreatment by saline solution
Study NCT00713674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraworx
Description: Theraworx swab intranasal BID for 5 days
Study NCT00713674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin antibiotic ointment
Description: mupirocin antibiotic ointment swab intranasal BID for 5 days
Study NCT00885989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV338
Description: 5 - 1000 mg IV
Study NCT00885989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01625923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD \< 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
Study NCT02590692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPCB-RPE1
Description: Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
Study NCT03105635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mixed method feasibility study
Description: Participating practices will receive the following:~1. Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~2. Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~3. Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~4. Navigator: The services of a Navigator
Study NCT04482270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: Oral
Study NCT03476408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlation / Observational
Description: correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
Study NCT04633629 — intervention group
Intervention type: OTHER
Intervention: Lung ultrasound
Description: We will perform daily a lung ultrasound to evaluate pulmonary congestion by counting B-lines.
Study NCT03005275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IVM
Description: FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter.
Study NCT03005275 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ICSI
Description: Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred
Study NCT01945970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black tea extract
Description: Black tea extract
Study NCT01945970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: Positive control
Study NCT01945970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03337945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basel phenotyping cocktail capsule
Description: Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling
Study NCT00504699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation in vitro fertilization cryopreservation
Description: Letrozole 5 mg/day during ovarian stimulation
Study NCT03477747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
Study NCT03477747 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microcurrent
Description: Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
Study NCT04537910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819253
Description: Administered SC.
Study NCT04537910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT00796705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: 40 mg injection of adalimumab administered subcutaneously
Study NCT00796705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab placebo
Description: 1.0 ml .9% saline placebo administered subcutaneously
Study NCT00796705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg dimeric fusion protein administered subcutaneously
Study NCT00747474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Description: Lipotecan IV day 1, 8, 15
Study NCT00575718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Counseling + Nicotine Replacement Therapy. questionaires
Description: brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status.